Divergent trial results on cancer vaccines have field grappling with hard questions
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of…
Eli Lilly’s Zepbound plus amylin drug led to major weight loss in mid-stage trial
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Pharmalittle: GLP-1s seen as lifestyle drugs; Merck, Daiichi setback
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating.…
Medicare’s AI prior authorization pilot was rushed, new documents reveal
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be…
Gifts from pharma companies keep on giving, a new study finds
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Mass General Brigham Medicare Advantage plan drops Dana-Farber
Eldon Clingan has had the same cancer specialist at Dana-Farber Cancer Institute for more than two decades. He…
FDA pilot offers generative AI medical devices a path to patients
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech;…
Amylyx endocrine drug succeeds in key study for low blood sugar
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Enveda weight loss maintenance pill mimics exercise in early tests
If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
Antitrust questions circling Epic Systems, nation’s largest EHR vendor
The Federal Trade Commission is examining Epic Systems Corp., the nation’s largest vendor of electronic health records, for…
Inside a $7 billion startup’s mad dash to automate the business of health care
Highlights Commure, a $7 billion technology company that uses AI to automate administrative tasks in health care, offers…
Stopping statins at 75 may be safe for healthy adults, Lancet study says
Not long after guidelines shifted to considering statin therapy as early as age 30, new research from France…